Alto Neuroscience, Inc. (ANRO) earnings date

NYSE · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 16 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 10, 2026after close 41 8-K
Q2 FY2026Wed, Aug 12, 2026after close 43 8-K
Q1 FY2026Wed, May 13, 2026before open 43 8-K
Q4 FY2025Mon, Mar 16, 2026before open 75 8-K
Q3 FY2025Wed, Nov 12, 2025before open 43 8-K
Q2 FY2025Wed, Aug 13, 2025after close 44 8-K
Q1 FY2025Wed, May 14, 2025after close 44 8-K
Q4 FY2024Thu, Mar 20, 2025after close 79 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights – PACE-1 trial of ALTO-207 in treatment-resistant depression (TRD) on track; topline data in 2H 2027 – – Phase 1 study results on the modified-release formulation of ALTO-207 and blinded PACE-1 safety data expected by early 2027; data expected to inform Phase 3 planning – – Strengthened balance sheet and extended cash runway with $100 million financing; cash position of $319.8 million expected to fund planned operations through 2030 – MOUNTAIN VIEW, Calif., November 10, 2026 – (" exhibit
Q3 FY2026 "Topline data are expected in 2H 2027." exhibit
Q3 FY2026 "PACE-2 (Phase 3, adjunctive TRD): Alto remains on track to initiate the trial in early 2027, pending alignment with the FDA on trial design." exhibit
Q3 FY2026 "Initiation is expected in 2H 2027, pending FDA alignment." exhibit
Q3 FY2026 "Alto expects to report the outcome of the FDA interaction and the Phase 1 data, along with blinded PACE-1 safety results in late 2026 or early 2027 following FDA feedback." exhibit
Q2 FY2026 "Document Exhibit 99.1 Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights – ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial; topline Phase 2b data on track for 2H 2027 – – Independent investigator-led study results published in Nature Medicine reinforce the dopaminergic mechanism underlying ALTO-207, demonstrating significant effects on anhedonia (Hedges' g=0.62, p=0.006) – – Approximatel" exhibit
Q2 FY2026 "With enrollment in our potentially registrational Phase 2b trial tracking as planned and pro forma cash of approximately $338 million, we are now positioned to pursue ALTO-207 in both the adjunctive and monotherapy settings, broadening the potential label and the commercial opportunity, with expected runway through 2030.”" exhibit
Q2 FY2026 "PACE-1 Trial (Phase 2b adjunctive TRD trial): Enrollment in the ongoing, potentially registrational, Phase 2b trial of ALTO-207 as an adjunctive treatment in approximately 178 adults with TRD is on track with topline data expected in 2H 2027." exhibit
Q2 FY2026 "PACE-2 Trial (Phase 3 adjunctive TRD trial) : Alto remains on track to initiate its Phase 3 trial of ALTO-207 as adjunctive treatment in TRD by early 2027, following alignment with the FDA on the planned trial design." exhibit
Q2 FY2026 "Alto expects to initiate this trial in the second half of 2027 pending alignment with the FDA." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ANRO
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ANRO

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ANRO earnings date badge

HTML

<a href="https://veritasdata.dev/company/ANRO/"><img src="https://veritasdata.dev/embed/ANRO.svg" alt="ANRO earnings date" width="240" height="56"></a>

Markdown

[![ANRO earnings date](https://veritasdata.dev/embed/ANRO.svg)](https://veritasdata.dev/company/ANRO/)

Script

<script async src="https://veritasdata.dev/embed/ANRO.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ANRO"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.